Haug ES - Search Results

1

Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.

Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Møller B. Nilssen Y, et al. Among authors: haug es. BMC Cancer. 2020 May 30;20(1):488. doi: 10.1186/s12885-020-06979-y. BMC Cancer. 2020. PMID: 32473650 Free PMC article.

2

Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway.

Andreassen BK, Myklebust TÅ, Haug ES. Andreassen BK, et al. Among authors: haug es. Scand J Urol. 2017 Feb;51(1):38-43. doi: 10.1080/21681805.2016.1271354. Epub 2017 Jan 13. Scand J Urol. 2017. PMID: 28084860

3

Tumour heterogeneity poses a significant challenge to cancer biomarker research.

Cyll K, Ersvær E, Vlatkovic L, Pradhan M, Kildal W, Avranden Kjær M, Kleppe A, Hveem TS, Carlsen B, Gill S, Löffeler S, Haug ES, Wæhre H, Sooriakumaran P, Danielsen HE. Cyll K, et al. Among authors: haug es. Br J Cancer. 2017 Jul 25;117(3):367-375. doi: 10.1038/bjc.2017.171. Epub 2017 Jun 15. Br J Cancer. 2017. PMID: 28618431 Free PMC article.

4

High Norwegian prostate cancer mortality: evidence of over-reporting.

Löffeler S, Halland A, Weedon-Fekjær H, Nikitenko A, Ellingsen CL, Haug ES. Löffeler S, et al. Among authors: haug es. Scand J Urol. 2018 Apr;52(2):122-128. doi: 10.1080/21681805.2017.1421260. Epub 2018 Jan 11. Scand J Urol. 2018. PMID: 29325479

5

Bladder cancer survival: Women better off in the long run.

Andreassen BK, Grimsrud TK, Haug ES. Andreassen BK, et al. Among authors: haug es. Eur J Cancer. 2018 May;95:52-58. doi: 10.1016/j.ejca.2018.03.001. Epub 2018 Apr 7. Eur J Cancer. 2018. PMID: 29635144 Free article.

6

T1 bladder cancer in Norway: treatment and survival.

Blindheim A, Fosså S, Babigumira R, Myklebust TÅ, Haug E, Arum CJ, Andreassen BK. Blindheim A, et al. Scand J Urol. 2020 Oct;54(5):370-375. doi: 10.1080/21681805.2020.1803401. Epub 2020 Aug 12. Scand J Urol. 2020. PMID: 32783590

7

Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival.

Fosså SD, Aas K, Müller C, Jerm MB, Tandstad T, Lilleby W, Kvåle R, Gulbrandsen J, Haug E, Myklebust TA. Fosså SD, et al. Radiother Oncol. 2021 Feb;155:33-41. doi: 10.1016/j.radonc.2020.10.022. Epub 2020 Oct 21. Radiother Oncol. 2021. PMID: 33096165 Free article.

8

Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016.

Nilssen Y, Brustugun OT, Eriksen MT, Guren MG, Haug ES, Naume B, Schlichting E, Møller B. Nilssen Y, et al. Among authors: haug es. BMC Cancer. 2022 Feb 28;22(1):220. doi: 10.1186/s12885-022-09306-9. BMC Cancer. 2022. PMID: 35227226 Free PMC article.

9

Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly.

Löffeler S, Halland A, Fawad H, Beisland C, Haug ES. Löffeler S, et al. Among authors: haug es. Scand J Urol. 2020 Apr;54(2):105-109. doi: 10.1080/21681805.2020.1732463. Epub 2020 Mar 5. Scand J Urol. 2020. PMID: 32133899

10

Work status and work ability after radical prostatectomy or active surveillance for prostate cancer.

Nilsson R, Dahl AA, Bernklev T, Kersten H, Haug ES. Nilsson R, et al. Among authors: haug es. Scand J Urol. 2020 Jun;54(3):194-200. doi: 10.1080/21681805.2020.1750473. Epub 2020 Apr 14. Scand J Urol. 2020. PMID: 32285740

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page